Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

NF-?B pathway in colitis-associated cancers in Translational Gastrointestinal Cancer, Emilie Viennois1, Fengyuan Chen1, Didier Merlin1, Department of Biology, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA; 2Department of Gastroenterology, Shanghai Fifth People’s Hospital, Fudan University, Shanghai 200240, People’s Republic of China; 3Veterans Affairs Medical Center, Decatur, GA, USA
Corresponding to: Emilie Viennois, Ph.D. Department of Biology, Center for Diagnostics and Therapeutics, Po Box 5090, Georgia State University, Atlanta, GA, 30303, USA., January 2013

Abstract:
Colitis-associated cancer is the subtype of colorectal cancer that is associated with inflammatory bowel diseases including ulcerative colitis and Crohn’s disease. Colorectal cancer is one of the most commonly diagnosed cancers, and is the third leading cause of cancer death in developed countries. Of the signaling pathways involved in colonic inflammation, that triggered by NF-?B plays a key role. A relationship between inflammation and cancer is now well documented. Moreover, the association between NF-?B activity and cancer development has been intensively investigated. The present review focuses on the activity of the NF-?B signaling pathway in colitis-associated carcinogenesis. The pivotal roles played by this pathway in apoptosis, tumor promotion, and tumor maintenance strongly suggest that inhibitors of the pathway would be powerful anti-cancer agents.

Article at:
http://www.amepc.org/tgc/article/view/1254/1878